Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Gastric Carcinoma and Its Clinical Significance_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 HANHong-bin , LIZhao-hui , LIUShuai-feng , DONGShuai-jun

Department of Gastrointestinal and Pancreatic Surgery, Affiliated Luoyang Central Hospital of Zhengzhou University, Luoyang 471009, Zhengzhou Province, China;

Corresponding author：

HANHong-bin, Email: hanhb132@sina.com

Keywords：

Gastric cancer; Circulating tumor cell; Immunomagnetic; Immunofluorescence staining

DOI：

10.7507/1007-9424.20150217

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To observe the detection of circulating tumor cells (CTCs) in peripheral blood of patients with gastric cancer, and to investigate the relationship between the CTCs and clinicalpathological features of gastric cancer. Methods Sixty cases of gastric cancer from September 2011 to September 2013 of our hospital were as the research object, and compared with 40 cases of benign gastric disease over the same period. These patients' venous blood were collected, the CTCs counts were determined by using the CellTracks AutoPrep fluorescence scaning system, and the relationship between CTCs and clinicopathological features of gastric cancer was analyzed. Results The detection rate of CTCs in gastric cancer patients was 70.0% (42/60), in control group was 7.5% (3/40). The positive rate of CTCs in peripheral blood of patients with gastric cancer was significantly higher than that of benign gastric disease (P<0.05). The positive rate of CTCs in peripheral blood were no correlated with gender, age, N staging, distant metastasis, tumor size, and vascular invasion (P>0.05), but were correlated with the TNM staging of tumor and degree of differentiation (P<0.05). The cumulative survival rates of 12 months and 18 months after operation in CTCs negtive patients with gastric cancer were higher than that CTCs positive patients (P<0.05). Conclusions The detection of CTCs is easy to manage and repeatable. The positive rate of CTCs in gastric patients is higher, which can reflect the progression of tumor and serve as the prognostic index in gastric cance patients.

Citation： HANHong-bin, LIZhao-hui, LIUShuai-feng, DONGShuai-jun. Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Gastric Carcinoma and Its Clinical Significance. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(7): 840-843. doi: 10.7507/1007-9424.20150217 Copy

1.	Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. Int J Cancer, 2010, 127(12):2893-2917.
2.	Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection:clinical impact and future directions. Cancer Lett, 2007, 253(2):180-204.
3.	kim DH,Oh CA,Oh SJ, et al.Validation of seventh edition AJCC gastric cancer staging modifications. J Surg Oncol, 2012, 105(1):26-30.
4.	Allan AL, Keeney M. Circulating tumor cell analysis:technical and statistical considerations for application to the clinic. J Oncol, 2010, 2010:426218.
5.	王蓓,吕成余,谢洪虎. 351例胃癌术后患者的预后因素分析. 中国普外基础与临床杂志,2012, 19(7):743-748.
6.	Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients:challenges and perspectives. Trends in Molecular Medicine, 2010, 16(9):398-406.
7.	Siewert JR. Gastric cancer:the dispute between East and West. Gastric Cancer, 2005, 8(2):59-61.
8.	Pantel K, Alix-Panabières C. Circulating tumour cells in cancer patients:challenges and perspectives. Trends Mol Med,2010, 16 (9):398-406.
9.	Cristofanilli M. The biological information obtainable from circulating tumor cells. Breast, 2009, 18 Suppl 3:S38-S40.
10.	Alunni-Fabbroni M, Sandri MT. Circulating tumour cells in clinical practice:Methods of detection and possible characterization. Methods, 2010, 50(4):289-297.
11.	Jung DE, Wen J, 0h T, et al. Differentially expressed mieroRNAs in pancreatic cancer stem cells. Pancreas, 2011, 40(8):1180-1187.
12.	Igawa S, Gohda K, Fukui T, et al. Circulating tumor cells as a prognostic factor in patients with small cell lung cancer. Oncol Lett, 2014, 7(5):1469-1473.
13.	Giordano A, Giuliano M, De Laurentiis M, et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer:lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol, 2012, 23(5):1144-1150.
14.	Galizia G, Gemei M, Orditura M, et al. Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients. J Gastrointest Surg, 2013, 17(10):1809-1818.
15.	Tibbe AG, Miller MC, Terstappen LW. Statistical considerations for enumeration of circulating tumor cells. Cytometry A, 2007, 71(3):154-162.
16.	Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res, 2004, 10(20):6897-6904.
17.	Arigami T, Uenosono Y, Hirata M, et al. B7-H3 expression in gastric cancer:a novel molecular blood marker for detecting circulating tumor cells. Cancer Sci,2011, 102(5):1019-1024.
18.	Mimori K, Fukagawa T, Kosaka Y, et al. A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bone marrow in gastric cancer cases. Ann Surg Oneol, 2008, 15(10):2934 2942.
19.	Kita Y, Fukagawa T, Mimori K, et al. Expression of uPAR mRNA in peripheral blood is a favourite marker for metastasis in gastric cancer cases. Br J Cancer, 2009, 100(1):153-159.
20.	Balic M, Williams A, Lin H, et al. Circulating tumor cells:from bench to bedside. Ann Rev Med, 2013, 64:31-44.
21.	Matsusaka S, Chìn K, Ogura M, et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer Sci, 2010, 101(4):1067-1071.
22.	Yie SM, Lou B, Ye SR, et al. Detection of survivin expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann Surg Oncol, 2008, 15(11):3073-3082.
23.	Uenosono Y, Arigami T, Kozono T, et al. Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer. Cancer, 2013, 119(22):3984-3991.
24.	Molloy TJ, Devriese LA, Helgason HH, et al. A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br J Cancer, 2011, 104(12):1913-1919.
25.	Sclafani F, Smyth E, Cunningham D, et al. Apilot study assessing the incidence and clinical significance of circulating tumor cells in esophagogastric cancers. Clin Colorectal Cancer, 2014, 13(2):94-99.
26.	Cohen SJ, PuntCJ, IannottiN, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol, 2008, 26(19):3213-3221.
27.	Tol J, Koopman M, Miller MC, et al. Circulating tumor cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agent. Ann Oncol, 2010, 21(5):1006-1012.

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. Int J Cancer, 2010, 127(12):2893-2917.
2. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection:clinical impact and future directions. Cancer Lett, 2007, 253(2):180-204.
3. kim DH,Oh CA,Oh SJ, et al.Validation of seventh edition AJCC gastric cancer staging modifications. J Surg Oncol, 2012, 105(1):26-30.
4. Allan AL, Keeney M. Circulating tumor cell analysis:technical and statistical considerations for application to the clinic. J Oncol, 2010, 2010:426218.
5. 王蓓,吕成余,谢洪虎. 351例胃癌术后患者的预后因素分析. 中国普外基础与临床杂志,2012, 19(7):743-748.
6. Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients:challenges and perspectives. Trends in Molecular Medicine, 2010, 16(9):398-406.
7. Siewert JR. Gastric cancer:the dispute between East and West. Gastric Cancer, 2005, 8(2):59-61.
8. Pantel K, Alix-Panabières C. Circulating tumour cells in cancer patients:challenges and perspectives. Trends Mol Med,2010, 16 (9):398-406.
9. Cristofanilli M. The biological information obtainable from circulating tumor cells. Breast, 2009, 18 Suppl 3:S38-S40.
10. Alunni-Fabbroni M, Sandri MT. Circulating tumour cells in clinical practice:Methods of detection and possible characterization. Methods, 2010, 50(4):289-297.
11. Jung DE, Wen J, 0h T, et al. Differentially expressed mieroRNAs in pancreatic cancer stem cells. Pancreas, 2011, 40(8):1180-1187.
12. Igawa S, Gohda K, Fukui T, et al. Circulating tumor cells as a prognostic factor in patients with small cell lung cancer. Oncol Lett, 2014, 7(5):1469-1473.
13. Giordano A, Giuliano M, De Laurentiis M, et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer:lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol, 2012, 23(5):1144-1150.
14. Galizia G, Gemei M, Orditura M, et al. Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients. J Gastrointest Surg, 2013, 17(10):1809-1818.
15. Tibbe AG, Miller MC, Terstappen LW. Statistical considerations for enumeration of circulating tumor cells. Cytometry A, 2007, 71(3):154-162.
16. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res, 2004, 10(20):6897-6904.
17. Arigami T, Uenosono Y, Hirata M, et al. B7-H3 expression in gastric cancer:a novel molecular blood marker for detecting circulating tumor cells. Cancer Sci,2011, 102(5):1019-1024.
18. Mimori K, Fukagawa T, Kosaka Y, et al. A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bone marrow in gastric cancer cases. Ann Surg Oneol, 2008, 15(10):2934 2942.
19. Kita Y, Fukagawa T, Mimori K, et al. Expression of uPAR mRNA in peripheral blood is a favourite marker for metastasis in gastric cancer cases. Br J Cancer, 2009, 100(1):153-159.
20. Balic M, Williams A, Lin H, et al. Circulating tumor cells:from bench to bedside. Ann Rev Med, 2013, 64:31-44.
21. Matsusaka S, Chìn K, Ogura M, et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer Sci, 2010, 101(4):1067-1071.
22. Yie SM, Lou B, Ye SR, et al. Detection of survivin expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann Surg Oncol, 2008, 15(11):3073-3082.
23. Uenosono Y, Arigami T, Kozono T, et al. Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer. Cancer, 2013, 119(22):3984-3991.
24. Molloy TJ, Devriese LA, Helgason HH, et al. A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br J Cancer, 2011, 104(12):1913-1919.
25. Sclafani F, Smyth E, Cunningham D, et al. Apilot study assessing the incidence and clinical significance of circulating tumor cells in esophagogastric cancers. Clin Colorectal Cancer, 2014, 13(2):94-99.
26. Cohen SJ, PuntCJ, IannottiN, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol, 2008, 26(19):3213-3221.
27. Tol J, Koopman M, Miller MC, et al. Circulating tumor cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agent. Ann Oncol, 2010, 21(5):1006-1012.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Gastric Carcinoma and Its Clinical Significance

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content